What are the best treatment options for a patient with primary infertility and adenomyosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Primary Infertility with Adenomyosis

For patients with primary infertility and adenomyosis, medical management (GnRH agonists) or uterine artery embolization (UAE) should be the initial therapy, with cytoreductive surgery reserved for severe cases unresponsive to first-line treatments. 1

Initial Treatment Algorithm

First-Line: Medical Management

  • GnRH agonists represent the primary medical therapy for adenomyosis in patients desiring pregnancy, as they suppress disease activity and can improve reproductive outcomes 2, 3
  • Medical management should be trialed for 3-6 months before pursuing more invasive therapies 1
  • After cytoreductive surgery (if performed), a 6-month course of GnRH agonist therapy is advisable before attempting conception, as adenomyosis tends to recur rapidly 3
  • Oral contraceptive pills, progestins, and danazol temporarily suppress the menstrual cycle and are not appropriate for patients actively pursuing pregnancy 2

Second-Line: Uterine Artery Embolization

  • UAE is usually appropriate for initial therapy in reproductive-age patients with adenomyosis and infertility 1
  • A retrospective study demonstrated spontaneous pregnancy rates of 29.5% at 1 year and 40.1% at 2 years following UAE, with a live birth rate of 81% 1
  • Long-term symptomatic relief ranges from 65% to 82% in patients with adenomyosis (median follow-up 27.9 months) 1
  • UAE should be considered for patients with concomitant adenomyosis and uterine leiomyomas 1

Surgical Options for Refractory Cases

Cytoreductive Surgery (Adenomyomectomy)

  • Cytoreductive surgery using Osada's approach should be reserved for severe adenomyosis unresponsive to medical management or UAE 4, 5
  • This procedure normalizes menstrual cycles and restores reproductive function in patients with severe disease 4
  • In one prospective study, spontaneous pregnancy occurred in 3 of 18 infertility patients (17%) after adenomyomectomy, with 2 delivering full-term babies 4
  • Surgery should be performed only by experienced surgeons in dedicated centers due to complexity and risk of myometrial disruption 3, 5
  • Delay pregnancy attempts for 4-6 months post-surgery to allow myometrial healing and complete GnRH agonist therapy 3

Important Surgical Considerations

  • Cytoreductive surgery is highly effective in ameliorating abnormal uterine bleeding and pelvic pain, but carries post-operative risks and potential obstetric complications 5
  • Major obstetric complications (uterine atony, rupture, placenta accreta) do not necessarily increase with adenomyosis during pregnancy, though cesarean delivery is typically recommended after extensive surgery 3
  • Hysterectomy remains the only definitive treatment but is obviously not appropriate for patients desiring fertility 2, 5

Emerging Technologies

High-Intensity Focused Ultrasound (HIFU)

  • HIFU may prove beneficial in adenomyosis patients planning pregnancy, though evidence remains limited 2
  • This non-invasive option preserves the uterus while targeting adenomyotic tissue 2

MR-Guided Focused Ultrasound (MRgFUS)

  • Evidence for MRgFUS in fertility enhancement is limited to case reports, and a randomized trial was terminated due to lack of enrollment 1
  • This modality should not be considered standard therapy for infertility with adenomyosis at this time 1

Assisted Reproductive Technology Integration

Combined Treatment Approach

  • Combined treatment with medical/surgical therapy before assisted reproductive techniques can prove beneficial in adenomyosis patients 2
  • After failed conservative treatments, progression to IVF/ICSI should be considered, as female partner age is a critical factor in fertility outcomes 6
  • Both partners should undergo concurrent assessment, as couple infertility may involve multiple factors 6, 7

Critical Pitfalls to Avoid

  • Never prescribe testosterone to patients desiring fertility, as it completely suppresses spermatogenesis through negative feedback 6, 8
  • Avoid delaying referral to assisted reproductive technology when conservative treatments fail, particularly in older patients 6
  • Do not perform endometrial ablation or other procedures that exclude pregnancy planning 2
  • Recognize that hormonal therapies (oral contraceptives, progestins, danazol) temporarily suppress menstruation and are not compatible with active conception attempts 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Adenomyosis and Infertility-Review of Medical and Surgical Approaches.

International journal of environmental research and public health, 2021

Research

Diffuse massive adenomyosis and infertility. Is it possible to treat this condition?

Hormone molecular biology and clinical investigation, 2019

Research

Conservative surgical treatment for adenomyosis: New options for looking beyond uterus removal.

Best practice & research. Clinical obstetrics & gynaecology, 2024

Guideline

Treatment for Male Patients with Low Sperm Motility (Asthenozoospermia)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Severe Male Factor Infertility with 90% Teratozoospermia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Nécrospermie Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.